Unique, practical knowledge for nurses responsible for daily management of patients with cardiovascular disease, diabetes and related conditions.

New diabetes QOF indicators recommended by NICE

New diabetes QOF indicators recommended by NICE

Publication date: Wednesday, 28 November 2018

An update of the QOF indicator list by NICE suggests that eight new diabetes indicators should be added to QOF from 2019/20. NICE says that the new approach, which comes following a review of the QOF in England, will improve outcomes and decrease the risk of harm from over-treatment.

Professor Gillian Leng, Deputy Chief Executive of NICE, said: “A number of the new NICE indicators for people with diabetes take account of frailty and are a step towards helping enable the greater personalisation of care. The intent of these indicators is to reduce the risk of treatment-related harm and improve the quality of life for people with moderate or severe frailty.”

Updated indicators on type 2 diabetes include two indicators on blood glucose targets for people with and without frailty, while another sets one blood pressure target for all people without frailty. Meanwhile, three new indicators feature which have been added since the consultation draft, supporting existing NICE recommendations on cardiovascular risk assessments and statin treatment for people with type 2 diabetes.

The QOF menu is used as part of GP contract negotiations, where the GPC and NHS England make final decisions about the final QOF list.

The new indicators are:

  • NM157 – The percentage of patients with diabetes without moderate or severe frailty, on the register, in whom the last IFCC-HbA1c is 58mmol/mol or less in the preceding 12 months.
  • NM158 – The percentage of patients with diabetes with moderate or severe frailty, on the register, in whom the last IFCC-HbA1c is 75mmol/mol or less in the preceding 12 months.
  • NM159 – The percentage of patients with diabetes without moderate or severe frailty, on the register, in whom the last blood pressure reading (measured in the preceding 12 months) is 140/80mmHg or less.
  • NM142 – The percentage of patients with type 1 diabetes who are aged over 40 years currently treated with a statin.
  • NM160 – The percentage of patients aged 25-84 years, with a diagnosis of type 2 diabetes, without moderate or severe frailty, not currently treated with a statin, who have had a consultation for a cardiovascular risk assessment using a risk assessment tool agreed with the NHS Commissioning Board in the last three years.
  • NM161 – The percentage of patients with a diagnosis of type 2 diabetes and a recorded CVD risk assessment score of ≥10% (without moderate or severe frailty), who are currently treated with a statin (unless there is a contraindication or statin therapy is declined).
  • NM162 – The percentage of patients with diabetes aged 40 years and over, with no history of CVD and without moderate or severe frailty, who are currently treated with a statin (excluding patients with type 2 diabetes and a CVD risk score of <10% recorded in the preceding 3 years).
  • NM163 – The percentage of patients with diabetes and a history of CVD (excluding haemorrhagic stroke) who are currently treated with a statin

 

More information

The full list of NICE’s proposed indicators can be found at: https://www.nice.org.uk/standards-and-indicators/qofindicators

 

READ MORE ARTICLES 

Heart failure: a syndrome of comorbidity

Case study: Statin intolerance in a patient with high cardiovascular risk

The NHS Health Check: a world leading non-communicable disease prevention programme

 

Topics covered:
Category: Have You Heard
Edition: Volume 3, Number 11, BJPCN Online 2018

Article search and filter